Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
47,649,567
-
Number of holders
-
77
-
Total 13F shares, excl. options
-
38,102,588
-
Shares change
-
+1,488,617
-
Total reported value, excl. options
-
$382,320,591
-
Value change
-
+$11,241,443
-
Put/Call ratio
-
200%
-
Number of buys
-
50
-
Number of sells
-
17
-
Price
-
$10.03
Institutional Holders of Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) as of Q1 2025
As of 31 Mar 2025 Rapport Therapeutics, Inc. - Common Stock, $0.001 par value per share (RAPP) had 77 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 38,102,588 shares of stock of the company.
Largest 10 holders included TRV GP V, LLC, FMR LLC, ARCH Venture Management, LLC, Cormorant Asset Management, LP, Capital International Investors, JOHNSON & JOHNSON, Sofinnova Investments, Inc., T. Rowe Price Investment Management, Inc., GOLDMAN SACHS GROUP INC, and BlackRock, Inc..
This table shows 77 institutional shareholders of the security as of 31 Mar 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.